Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia-Reference-Cited by-同舟云学术

Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia

Published:2020-02-22 Issue:6 Volume:188 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Giona Fiorina¹^ORCID,Malaspina Francesco¹^ORCID,Putti Maria Caterina²,Ladogana Saverio³,Mura Rosamaria⁴,Burnelli Roberta⁵,Vacca Nadia⁶,Rizzo Lorenzo¹,Bianchi Simona¹,Moleti Maria Luisa¹^ORCID,Testi Anna Maria¹,Biondi Andrea⁷,Locatelli Franco⁸^ORCID,Saglio Giuseppe⁹^ORCID,Foà Robin¹

Affiliation:

1. Department of Translational and Precision Medicine Sapienza University Rome Italy

2. Hemato‐Oncology Unit Department of Women’s and Children’s Health University of Padua Padua Italy

3. Department of Pediatrics Hemato‐Oncology Unit ‘Casa Sollievo della Sofferenza’ Hospital San Giovanni Rotondo Italy

4. Pediatric Hemato‐Oncology Unit Ospedale Regionale per le Microcitemie Cagliari Italy

5. Pediatric Hemato‐Oncology Unit Sant’Anna Hospital Ferrara Italy

6. Pediatric Unit Ospedale di Sassari Sassari Italy

7. Department of Pediatrics University of Milano‐Bicocca Monza Italy

8. Department of Pediatrics Pediatric Hematology‐Oncology University of Pavia IRCCS Ospedale Pediatrico Bambino Gesù Rome Italy

9. Department of Clinical and Biological Sciences University of Turin at Orbassano Turin Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16388

Reference14 articles.

1. Imatinib has adverse effect on growth in children with chronic myeloid leukemia

2. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing

3. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty

4. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience

5. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Autologous Hematopoietic Stem Cell Transplantation: Safety, Efficacy, and Patient Outcomes. Literature Review;Pediatric Health, Medicine and Therapeutics;2023-05

2. Update in Childhood Chronic Myeloid Leukemia;Hemato;2022-11-05

3. Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection;Cancer Reports;2022-07-07

4. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia;Pediatric Blood & Cancer;2022-04-11

5. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study;Annals of Hematology;2021-06-05